Poly(amido)amine (PAMAM) dendrimer-cisplatin complexes for chemotherapy of cisplatin-resistant ovarian cancer cells

Journal of Nanoparticle Research

Volumn 15, Issue 9, 2013, Pages

  Yellepeddi, Venkata Kashyap ^a   Vangara, Kiran Kumar ^a   Palakurthi, Srinath ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Apoptosis; Cellular uptake; Dendrimer cisplatin complexes; DNA Pt adducts; Nucleotide excision repair; Ovarian cancer

Indexed keywords

CARBOXYLATION; CELL CULTURE; CELL DEATH; CHEMOTHERAPY; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DISEASES; INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY;

CELLULAR UPTAKE; CIS-PLATIN; INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRIES (ICPMS); NUCLEOTIDE EXCISION REPAIR; OVARIAN CANCER CELLS; OVARIAN CANCERS; PAMAM DENDRIMER; PRE FORMULATIONS;

DENDRIMERS;

AMINE; BIOTIN; CARBOXYLIC ACID; CASPASE 3; CASPASE 8; CISPLATIN; DENDRIMER; PLATINUM; POLYAMIDOAMINE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTICLE; BIOTINYLATION; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DNA ADDUCT; DRUG CYTOTOXICITY; DRUG UPTAKE; ENZYME ACTIVITY; EXCISION REPAIR; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MASS SPECTROMETRY; NONHUMAN; OVARY CANCER; PREFORMULATION; PRIORITY JOURNAL;

EID: 84881066929     PISSN: 13880764     EISSN: 1572896X     Source Type: Journal    
DOI: 10.1007/s11051-013-1897-6     Document Type: Article

References (45)

1. American Cancer Society (2011) Ovarian cancer-detailed guide-ovarian cancer key statistics. www.cancer.org
2. Andrews PA (1994) Mechanisms of acquired resistance to cisplatin. Cancer Treat Res 73:217-248
3. Boulikas T (2009) Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin. Expert Opin Investig Drugs 18(8):1197-1218. doi:10.1517/13543780903114168
4. Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen RH, Wiemer EA (2011) Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat 14(1):22-34. doi:10.1016/j.drup.2010.12.002
5. Casalini P, Luison E, Menard S, Colnaghi MI, Paganelli G, Canevari S (1997) Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization. J Nucl Med 38(9):1378-1381 (Pubitemid 27386193)
6. Cheng EH, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, Ueno K, Hardwick JM (1997) Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 278(5345):1966-1968 (Pubitemid 28013242)
7. Echarri Gonzalez MJ, Green R, Muggia FM (2011) Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when? Oncology (Williston Park) 25(2): 156-165
8. El-Sayed M, Rhodes CA, Ginski M, Ghandehari H (2003) Transport mechanism(s) of poly (amidoamine) dendrimers across Caco-2 cell monolayers. Int J Pharm 265(1-2):151-157 (Pubitemid 37176956)
9. Fischer U, Janicke RU, Schulze-Osthoff K (2003) Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 10(1):76-100. doi:10.1038/sj.cdd.4401160 (Pubitemid 36511834)
10. Grandgirard D, Studer E, Monney L, Belser T, Fellay I, Borner C, Michel MR (1998) Alphaviruses induce apoptosis in Bcl-2-overexpressing cells: evidence for a caspase-mediated, proteolytic inactivation of Bcl-2. EMBO J 17(5):1268-1278. doi:10.1093/emboj/17.5.1268 (Pubitemid 28105506)
11. Gryparis EC, Hatziapostolou M, Papadimitriou E, Avgoustakis K (2007) Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells. Eur J Pharm Biopharm 67(1):1-8. doi:10.1016/j.ejpb.2006. 12.017 (Pubitemid 46991325)
12. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8(3):193-204. doi:10.1038/nrc2342 (Pubitemid 351301852)
13. Ho YP, Au-Yeung SC, To KK (2003) Platinum-based anticancer agents: innovative design strategies and biological perspectives. Med Res Rev 23(5):633-655. doi:10.1002/med.10038 (Pubitemid 37038095)
14. Jevprasesphant R, Penny J, Attwood D, D'Emanuele A (2004) Transport of dendrimer nanocarriers through epithelial cells via the transcellular route. J Control Release 97(2):259-267. doi:10.1016/j.jconrel.2004.03.022 (Pubitemid 38759483)
15. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7(8):573-584. doi:10.1038/nrc2167
16. Kim YM, Kim TH, Seol DW, Talanian RV, Billiar TR (1998) Nitric oxide suppression of apoptosis occurs in association with an inhibition of Bcl-2 cleavage and cytochrome c release. J Biol Chem 273(47):31437-31441 (Pubitemid 28533163)
17. Kirkpatrick GJ, Plumb JA, Sutcliffe OB, Flint DJ, Wheate NJ (2011) Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin. J Inorg Biochem 105(9):1115-1122. doi:10.1016/j.jinorgbio.2011.05.017
18. Kojima C, Kono K, Maruyama K, Takagishi T (2000) Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug Chem 11(6):910-917
19. Kolishetti N, Dhar S, Valencia PM, Lin LQ, Karnik R, Lippard SJ, Langer R, Farokhzad OC (2010) Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci USA 107(42):17939-17944. doi:10.1073/pnas.1011368107
20. Li H, Zhu H, Xu CJ, Yuan J (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94(4):491-501 (Pubitemid 28391865)
21. Malik N, Evagorou EG, Duncan R (1999) Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 10(8):767-776 (Pubitemid 30015678)
22. Mamede M, Saga T, Kobayashi H, Ishimori T, Higashi T, Sato N, Brechbiel MW, Konishi J (2003) Radiolabeling of avidin with very high specific activity for internal radiation therapy of intraperitoneally disseminated tumors. Clin Cancer Res 9(10 Pt 1):3756-3762 (Pubitemid 37169245)
23. Marques-Gallego P, Kalayda GV, Jaehde U, Dulk H, Brouwer J, Reedijk J (2009) Cellular accumulation and DNA platination of two new platinum(II) anticancer compounds based on anthracene derivatives as carrier ligands. J Inorg Biochem 103(5):791-796. doi:10.1016/j.jinorgbio.2009.02.005
24. Nishiyama N, Kataoka K (2001) Preparation and characterization of size-controlled polymeric micelle containing cis-dichlorodiammineplatinum(II) in the core. J Control Release 74(1-3):83-94 (Pubitemid 32727612)
25. Nishiyama N, Kato Y, Sugiyama Y, Kataoka K (2001) Cis-platin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system. Pharm Res 18(7):1035-1041 (Pubitemid 32799952)
26. Park JH, von Maltzahn G, Xu MJ, Fogal V, Kotamraju VR, Ruoslahti E, Bhatia SN, Sailor MJ (2010) Cooperative nanomaterial system to sensitize, target, and treat tumors. Proc Natl Acad Sci USA 107(3):981-986. doi:10.1073/pnas.0909565107
27. Perez RP (1998) Cellular and molecular determinants of cis-platin resistance. Eur J Cancer 34(10):1535-1542
28. Piccart MJ, Lamb H, Vermorken JB (2001) Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol 12(9):1195-1203 (Pubitemid 32994741)
29. Prasad PD, Wang H, Kekuda R, Fujita T, Fei YJ, Devoe LD, Leibach FH, Ganapathy V (1998) Cloning and functional expression of a cDNA encoding a mammalian sodium-dependent vitamin transporter mediating the uptake of pantothenate, biotin, and lipoate. J Biol Chem 273(13):7501-7506
30. Prasad PD, Wang H, Huang W, Fei YJ, Leibach FH, Devoe LD, Ganapathy V (1999) Molecular and functional characterization of the intestinal Na?-dependent multivitamin transporter. Arch Biochem Biophys 366(1):95-106. doi:10.1006/abbi.1999.1213 (Pubitemid 29394234)
31. Reedijk J, Lohman PH (1985) Cisplatin: synthesis, antitumour activity and mechanism of action. Pharm Weekbl Sci 7(5):173-180 (Pubitemid 15225079)
32. Russell-Jones G, McTavish K, McEwan J, Rice J, Nowotnik D (2004) Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. J Inorg Biochem 98(10):1625-1633. doi:10.1016/j.jinorgbio.2004.07.009 (Pubitemid 39349188)
33. Russell-Jones G, McTavish K, McEwan J (2011) Preliminary studies on the selective accumulation of vitamin-targeted polymers within tumors. J Drug Target 19(2):133-139. doi:10.3109/10611861003734027
34. Seib FP, Jones AT, Duncan R (2007) Comparison of the endocytic properties of linear and branched PEIs, and cationic PAMAM dendrimers in B16f10 melanoma cells. J Control Release 117(3):291-300. doi:10.1016/j.jconrel.2006.10.020 (Pubitemid 46216575)
35. Shahzad MM, Lopez-Berestein G, Sood AK (2009) Novel strategies for reversing platinum resistance. Drug Resist Updat 12(6):148-152. doi:10.1016/j.drup.2009.09.001
36. Tamura T, Imai J, Matsumoto A, Tanimoto M, Suzuki A, Horikiri Y, Suzuki T, Yoshino H, Ike O (2002) Organ distribution of cisplatin after intraperitoneal administration of cisplatin-loaded microspheres. Eur J Pharm Biopharm 54(1):1-7 (Pubitemid 34663850)
37. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS, Dixit VM (1995) Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmAinhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81(5):801-809
38. Wilbur DS, Pathare PM, Hamlin DK, Buhler KR, Vessella RL (1998) Biotin reagents for antibody pretargeting. 3. Synthesis, radioiodination, and evaluation of biotinylated starburst dendrimers. Bioconjug Chem 9(6):813-825.doi:10.1021/bc980055e (Pubitemid 28542250)
39. Yan X, Gemeinhart RA (2005) Cisplatin delivery from poly(-acrylic acid-co-methyl methacrylate) microparticles. J Control Release 106(1-2):198-208. doi:10.1016/j.jconrel.2005.05.005 (Pubitemid 41149078)
40. Yellepeddi VK, Kumar A, Palakurthi S (2009a) Biotinylated poly(amido)amine (PAMAM) dendrimers as carriers for drug delivery to ovarian cancer cells in vitro. Anticancer Res 29(8):2933-2943
41. Yellepeddi VK, Kumar A, Palakurthi S (2009b) Surface modified poly(amido)amine dendrimers as diverse nanomolecules for biomedical applications. Expert Opin Drug Deliv 6(8):835-850. doi:10.1517/17425240903061251
42. Yellepeddi VK, Kumar A, Maher DM, Chauhan SC, Vangara KK, Palakurthi S (2011) Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: role of SMVT. Anticancer Res 31(3):897-906
43. Zhang XM, Lin H, Chen C, Chen BD (1999) Inhibition of ubiquitin-proteasome pathway activates a caspase-3-like protease and induces Bcl-2 cleavage in human M-07e leukaemic cells. Biochem J 340(Pt 1):127-133 (Pubitemid 29251099)
44. Zhu J, Xiong L, Yu B, Wu J (2005) Apoptosis induced by a new member of saponin family is mediated through caspase-8-dependent cleavage of Bcl-2. Mol Pharmacol 68(6):1831-1838. doi:10.1124/mol.105.015826 (Pubitemid 41656029)
45. Zhu J, Yang Y, Wu J (2007) Bcl-2 cleavages at two adjacent sites by different caspases promote cisplatin-induced apoptosis. Cell Res 17(5):441-448. doi:10.1038/cr.2007.36 (Pubitemid 46763095)